MUMBAI, India, Jan. 9 -- Intellectual Property India has published a patent application (202521110314 A) filed by Yeshwant Ramchandra Bhorge; N. Swetha,; Dr J. V. Madhuri; K. R. Manjula; Sudha Varalakshmi; Mr. Prabu V; Dr. P. Durairaj; Mr. Kapil Gupta; and Dr. Raji Thomas, Nagpur, Maharashtra, on Nov. 12, 2025, for 'nanotechnology-based drug delivery system for targeted cancer therapy using biochemical markers.'
Inventor(s) include Yeshwant Ramchandra Bhorge; N. Swetha; Dr J. V. Madhuri; K. R. Manjula; Sudha Varalakshmi; Mr. Prabu V; Dr. P. Durairaj; Mr. Kapil Gupta; and Dr. Raji Thomas.
The application for the patent was published on Dec. 12, under issue no. 50/2025.
According to the abstract released by the Intellectual Property India: "The invention utilizes nanoparticles functionalized with specific ligands, antibodies, peptides, or aptamers that recognize and bind to biochemical markers uniquely or overexpressed on cancer cells. By exploiting these molecular differences between malignant and healthy tissues, the system delivers therapeutic agents directly to tumor sites, significantly reducing systemic toxicity and side effects associated with conventional chemotherapy. The nanoparticles, typically ranging from 1 to 100 nanometers, act as carriers for various therapeutic agents, including chemotherapeutic drugs, peptides, and biologics. These nanoparticles can be engineered to respond to tumor-specific stimuli, such as changes in pH, enzymatic activity, or temperature, allowing for controlled and sustained release of the drug within the tumor microenvironment. The surface functionalization of nanoparticles enhances selectivity, improves drug stability and solubility, and increases circulation time, ensuring optimal therapeutic concentration at the target site. This invention further allows for multi-marker targeting, enabling recognition of multiple biochemical markers simultaneously to address tumor heterogeneity and drug resistance. It can also incorporate diagnostic agents, enabling theranostic applications for simultaneous treatment and real-time monitoring of tumor response. The system's biocompatible and biodegradable design ensures safe metabolism and elimination after drug delivery. Overall, the invention represents a significant advancement in cancer therapy by combining nanotechnology, biochemical targeting, and controlled drug release into a single, adaptable platform. It enhances therapeutic efficacy, minimizes off-target effects, and supports the development of personalized cancer treatments, making it a promising solution for precise and effective management of various cancer types."
Disclaimer: Curated by HT Syndication.
